These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 23489710)

  • 1. Expectations about insulin therapy, perceived insulin-delivery system social acceptability, and insulin treatment satisfaction contribute to decreases in insulin therapy self-efficacy in patients with type 2 diabetes after 36 weeks insulin therapy.
    Hayes RP; Curtis B; Ilag L; Nelson DR; Wong M; Funnell M
    J Diabetes; 2013 Sep; 5(3):358-67. PubMed ID: 23489710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The contribution of pretreatment expectations and expectation-perception difference to change in treatment satisfaction and end point treatment satisfaction in the context of initiation of inhaled insulin therapy in patients with type 2 diabetes.
    Hayes RP; Naegeli AN
    Diabetes Technol Ther; 2010 Jun; 12(6):447-53. PubMed ID: 20470229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perceptions and attitudes are primary contributors to insulin delivery system satisfaction in people with type 2 diabetes.
    Hayes RP; Fitzgerald JT
    Diabetes Technol Ther; 2009 Jul; 11(7):419-26. PubMed ID: 19580354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expectations about and experiences with insulin therapy contribute to diabetes treatment satisfaction in insulin-naïve patients with type 2 diabetes.
    Naegeli AN; Hayes RP
    Int J Clin Pract; 2010 Jun; 64(7):908-16. PubMed ID: 20370840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycemic control with Humalog Mix25 in type 2 diabetes inadequately controlled with glyburide.
    Roach ; Koledova E; Metcalfe S; Hultman C; Milicevic Z;
    Clin Ther; 2001 Oct; 23(10):1732-44. PubMed ID: 11726007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Web-based guided insulin self-titration in patients with type 2 diabetes: the Di@log study. Design of a cluster randomised controlled trial [TC1316].
    Roek MG; Welschen LM; Kostense PJ; Dekker JM; Snoek FJ; Nijpels G
    BMC Fam Pract; 2009 Jun; 10():40. PubMed ID: 19508712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of Basal-Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen.
    Bergenstal RM; Peyrot M; Dreon DM; Aroda VR; Bailey TS; Brazg RL; Frias JP; Johnson ML; Klonoff DC; Kruger DF; Ramtoola S; Rosenstock J; Serusclat P; Weinstock RS; Naik RG; Shearer DM; Zraick V; Levy BL;
    Diabetes Technol Ther; 2019 May; 21(5):273-285. PubMed ID: 31025878
    [No Abstract]   [Full Text] [Related]  

  • 9. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
    Weng J
    J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes.
    Secnik Boye K; Matza LS; Oglesby A; Malley K; Kim S; Hayes RP; Brodows R
    Health Qual Life Outcomes; 2006 Oct; 4():80. PubMed ID: 17034640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial.
    Yang J; Xiao W; Guo L; Li Q; Zhong L; Yang J; Yang J; Gao Y; Tian Q; Hong T
    Acta Diabetol; 2020 Aug; 57(8):991-1000. PubMed ID: 32206903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study Protocol for a Prospective, Multicenter, Randomized, Open-Label, Parallel-Group Clinical Trial Comparing the Efficacy and Safety of a Needle-Free Insulin Injector and a Conventional Insulin Pen in Controlling Blood Glucose Concentrations in Chinese Patients with Type 2 Diabetes Mellitus (The FREE Study).
    Ji L; Chen L; Wang Y; Ma Z; Ran X; Sun Z; Xu X; Wang G; Guo L; Shan Z
    Adv Ther; 2019 Jun; 36(6):1485-1496. PubMed ID: 31004325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. More satisfied, but why? A pooled patient-level analysis of treatment satisfaction following the initiation of insulin glargine vs. comparators in insulin-naïve patients with type 2 diabetes mellitus.
    Polonsky W; Traylor L; Wei W; Shi R; Ameer B; Vlajnic A; Nicolucci A
    Diabetes Obes Metab; 2014 Mar; 16(3):255-61. PubMed ID: 24028669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen.
    Cappelleri JC; Cefalu WT; Rosenstock J; Kourides IA; Gerber RA
    Clin Ther; 2002 Apr; 24(4):552-64. PubMed ID: 12017400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes: Empowerment Perceptions and Diabetes Distress as Important Determinants.
    Chen SY; Hsu HC; Wang RH; Lee YJ; Hsieh CH
    Biol Res Nurs; 2019 Mar; 21(2):182-189. PubMed ID: 30585081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
    Jacober SJ; Scism-Bacon JL; Zagar AJ
    Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial.
    Gough SC; Bhargava A; Jain R; Mersebach H; Rasmussen S; Bergenstal RM
    Diabetes Care; 2013 Sep; 36(9):2536-42. PubMed ID: 23715753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
    Rosenstock J; Jelaska A; Frappin G; Salsali A; Kim G; Woerle HJ; Broedl UC;
    Diabetes Care; 2014 Jul; 37(7):1815-23. PubMed ID: 24929430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of sitagliptin added to insulin in Japanese patients with type 2 diabetes: the EDIT randomized trial.
    Sato S; Saisho Y; Kou K; Meguro S; Tanaka M; Irie J; Kawai T; Itoh H
    PLoS One; 2015; 10(3):e0121988. PubMed ID: 25816296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in insulin treatment satisfaction following randomized addition of biphasic, prandial or basal insulin to oral therapy in type 2 diabetes.
    Farmer AJ; Oke J; Stevens R; Holman RR
    Diabetes Obes Metab; 2011 Dec; 13(12):1136-41. PubMed ID: 21767341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.